Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MaxCyte Inc.

www.maxcyte.com

Latest From MaxCyte Inc.

Deal Watch: Oncternal Goes Public Via Reverse Merger With GTx

All-stock transaction combines privately held Oncternal with GTx, which had been considering its strategic alternatives. Biogen acquires gene therapy biotech Nightstar, MaxCyte and Kite expand their CAR-T partnership.

Deals Business Strategies

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.

Deals Business Strategies

Partnering In Cell And Gene Therapy Is A Unique Endeavor

Industry and academic representatives shared viewpoints at Biotech Week Boston in September 2018, including what is unique about deal-making in the cell and gene field.

Regenerative Medicine Deals

CRISPR Therapeutics, Vertex Initiate First Industry-Sponsored Trial – What’s Next?

CRISPR Therapeutics and Vertex initiated the first human study of CRISPR gene-editing technology with an industry sponsor, following an investigator-sponsored study initiated in China two years ago. These are not the first gene-editing trials, but they're important milestones for the CRISPR field.

Clinical Trials Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
  • Services
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • TheraMed Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • MaxCyte Inc.
  • Senior Management
  • Douglas A Doerfler, Pres. & CEO
    Ronald Holtz, CFO
    Deborah K Bowes, EVP, Bus. & Strategic Dev.
    Madhusudan Peshwa, PhD, CSO, EVP, Cellular Therapies
    Thomas M Ross, EVP, Global Sales
  • Contact Info
  • MaxCyte Inc.
    Phone: (301) 944-1700
    22 Firstfield Road
    St. 250
    Gaithersburg, MD 20878
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register